South Dakota Investment Council Sells 3,000 Shares of Regeneron Pharmaceuticals, Inc. $REGN

South Dakota Investment Council lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 20.6% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 11,578 shares of the biopharmaceutical company’s stock after selling 3,000 shares during the period. South Dakota Investment Council’s holdings in Regeneron Pharmaceuticals were worth $8,779,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in REGN. LCM Capital Management Inc increased its position in shares of Regeneron Pharmaceuticals by 2.2% during the 3rd quarter. LCM Capital Management Inc now owns 616 shares of the biopharmaceutical company’s stock valued at $467,000 after purchasing an additional 13 shares during the last quarter. Oakworth Capital Inc. increased its position in shares of Regeneron Pharmaceuticals by 25.0% during the third quarter. Oakworth Capital Inc. now owns 70 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 14 shares in the last quarter. Kestra Investment Management LLC increased its stake in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Kestra Investment Management LLC now owns 675 shares of the biopharmaceutical company’s stock valued at $512,000 after purchasing an additional 16 shares in the last quarter. Glenview Trust Co increased its holdings in shares of Regeneron Pharmaceuticals by 0.4% in the third quarter. Glenview Trust Co now owns 4,421 shares of the biopharmaceutical company’s stock valued at $3,352,000 after purchasing an additional 17 shares during the period. Finally, Bingham Private Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.7% during the third quarter. Bingham Private Wealth LLC now owns 473 shares of the biopharmaceutical company’s stock worth $359,000 after purchasing an additional 17 shares during the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $945.53 on Thursday. The stock’s 50-day simple moving average is $824.37 and its 200-day simple moving average is $750.43. The firm has a market capitalization of $97.81 billion, a PE ratio of 20.88, a price-to-earnings-growth ratio of 1.27 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $591.52 and a fifty-two week high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.35.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. During the same quarter in the previous year, the firm earned $11.83 EPS. The company’s revenue was up 36.3% compared to the same quarter last year. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Friday, November 20th. Regeneron Pharmaceuticals’s payout ratio is presently 8.30%.

Recent Regeneron Pharmaceuticals Headlines

Here are a few of the latest headlines about REGN:

  • Positive Sentiment: The FDA approved Livsayis (cemdisiran) for adults with generalized myasthenia gravis. Regeneron says it is the first approved siRNA therapy for the condition and offers subcutaneous dosing four times a year. The approval, based on Phase 3 NIMBLE results, gives Regeneron its first approved siRNA medicine and neurology product, creating a potential new commercial franchise. Livsayis FDA approval
  • Positive Sentiment: Barclays raised its price target on REGN to $1,075 from $917 and maintained an Overweight rating, signaling a more bullish view of the shares. Barclays price-target change
  • Neutral Sentiment: Regeneron plans to present data from 14 hematology abstracts at the December ASH meeting, including potentially pivotal Ordspono data in relapsed or refractory marginal zone lymphoma. The presentations could inform the pipeline outlook, but the data have not yet been disclosed. ASH 2026 hematology data announcement

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Kathryn Guarini sold 400 shares of the firm’s stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $900.00, for a total transaction of $360,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $542,700. This trade represents a 39.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Joseph J. Larosa sold 4,466 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $965.49, for a total transaction of $4,311,878.34. Following the completion of the transaction, the executive vice president directly owned 38,906 shares in the company, valued at $37,563,353.94. The trade was a 10.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 27,028 shares of company stock worth $25,025,950. Insiders own 6.97% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on REGN. Jefferies Financial Group raised their price objective on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. The Goldman Sachs Group lifted their price target on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. UBS Group upgraded Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $660.00 to $978.00 in a report on Thursday, October 15th. Finally, Robert W. Baird increased their price objective on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the stock a “neutral” rating in a research report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $904.41.

Get Our Latest Stock Analysis on REGN

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.